Despite the use of current first-line treatment i.e., the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL), the rates of relapse remain high.1 Eventually, there came a breakthrough on April 19, 2023, when the Unit

Since the introduction of anthracyclines, they have been associated with cumulative and dose-dependent cardiotoxicity.¹ The updated European Society of Cardiology (ESC) guidelines endorse echocardiography (ECG) assessments at baseline and 12 months of treatment, with further surveillance if the cumulative dose reaches an equivalence of doxorubicin 250mg/m².² Of note, previous studies reported a cumulative decrease in left ventricular ejection fraction (LVEF).¹ However, in a recent retrospective case-controlled report, there was no significant difference in the chronic heart failure (CHF) risk based on cumulative anthracycline dose, and that among cancer patients who were not treated with anthracyclines, the risk of CHF was also not statistically significant compared with healthy controls.²

Chromosome arm 1q gain (1q+) is among the most common cytogenetic abnormalities in multiple myeloma (MM).MM patients with 1q+ have recently been proven to have a worse prognosis than standard-risk patients, and 1q+ has also been recognized as an independent adverse factor for overall survival (OS) in MM patients.¹ During the 2022 Annual Scientific Meeting of the Hong Kong Society of Myeloma, Professor Thomas G. Martin discussed the classification, current evidence, and clinical advancement of high-risk MM with reference to the relevant international guidelines or scoring system, highlighting the new inclusion of 1q+ in the most recent second revision of the International Staging System (R2-ISS). He also discussed a management algorithm for newly diagnosed as well as relapsed or refractory MM (RRMM) patients, and presented isatuximab (Isa) related data which showed a significant benefit when combining Isa with carfilzomib and dexamethasone (Kd), or pomalidomide and dexamethasone (Pd).